Original reporting and analysis on the stories shaping biotech.
Olympus, the company behind 70% of the world's GI endoscopes, just dropped $270 million on a tiny Israeli startup that makes biodegradable balloons for cancer treatment. The deal signals a bold pivot from finding tumors to helping treat them.
The team behind MyoKardia's $13.1 billion sale to Bristol Myers Squibb just filed for an IPO under ticker KARD, armed with three late-stage heart drugs and over half a billion in private funding. In a 2026 IPO market dominated by oncology, Kardigan is making a contrarian bet on cardiovascular disease.
Congress wants to expand a national security law to cover biotech, potentially disrupting a $137 billion China-to-U.S. licensing boom. The COINS Act could force every cross-border deal through a government screening process, and Big Pharma's favorite pipeline is in the crosshairs.
KRAS inhibitors were supposed to revolutionize cancer treatment, but tumors keep finding workarounds. Kura Oncology just dropped early clinical data on a companion drug designed to shut down cancer's favorite escape route, and the implications could reshape one of oncology's most competitive markets.
The FDA says a nationwide shortage of basic neurosurgical sponges and patties will last through the end of 2026, after Medline recalled its entire neuro sponge line over bacterial toxin contamination. Hospitals are now rationing supplies for brain surgery.
Eli Lilly is selling Zepbound's highest doses in cheaper vials at $449/month, roughly 60% below pen prices. It looks like a price cut, but Wall Street says it's actually a volume play that won't hurt Lilly's bottom line.
CellCentric just closed a $220 million Series D, the largest private biotech financing in Europe this year, to push its first-in-class oral cancer drug toward approval. In a market where investors have been stingy with late-stage oncology bets, this oversubscribed round tells a bigger story about what it takes to get funded in 2026.
Eli Lilly dropped up to $3.8 billion to acquire three vaccine companies in a single day, targeting everything from shingles to Epstein-Barr virus. It's the biggest bet on vaccines by a non-vaccine company in years, and it signals a radical strategic shift.
The FDA launched an AI-powered pilot that compresses traditional week-long factory inspections into a single day. With nearly 2,000 facilities overdue for routine visits and inspector vacancies at four times pre-pandemic levels, the algorithm is now deciding who gets the speed run and who gets the deep dive.
The FDA just asked the public to help design an AI clinical trial pilot program, with selections planned for August 2026. This isn't a vague exploration; it's a live procurement process that could set the rules for AI in drug development for years to come.
Astellas Pharma's biggest drug generates over 40% of its revenue and loses U.S. patent protection in 2027. The company just laid out an aggressive plan to buy, partner, and cut its way through the storm, and it's adding serious heat to an already competitive biotech M&A market.
The FDA just proved it can watch clinical trial data in real time, not months after the fact. AstraZeneca and Amgen are the first guinea pigs in an initiative that could cut drug development timelines by up to 40%.
After 25 years in the making, the FDA just approved the first-ever PROTAC drug: a pill that tricks cancer cells into destroying their own proteins. Veppanu's modest clinical results mask a potentially massive shift in how we think about treating disease.
Terns Pharmaceuticals ditched its entire metabolic disease pipeline to bet on a single cancer drug. Merck just validated that gamble with a $6.7 billion all-cash acquisition, and Wall Street thinks it got a bargain.
Sun Pharma is paying $11.75 billion for Organon in the largest overseas acquisition ever by an Indian pharma company. Wall Street had all but written Organon off, with zero Buy ratings and a stock trading near $6, before a 103% premium cash offer changed everything.
Chiesi Group, a privately held Italian pharma company, is dropping $1.9 billion to buy KalVista and its first-of-its-kind oral pill for hereditary angioedema attacks. The deal tells a bigger story about what rare disease assets are really worth.
Roche is spending up to $1.05 billion to acquire PathAI, one of the most advanced AI pathology platforms in the world. The deal could reshape how companion diagnostics are built, how clinical trials are run, and who controls the future of cancer diagnosis.
Eli Lilly is pushing a gene-editing therapy into Phase 2 that could permanently slash cholesterol with a single infusion. It's the biggest bet yet that CRISPR-era medicine can tackle the world's leading killer, not just rare diseases.
Gilead just agreed to pay up to $2.2 billion for Ouro Medicines, a startup that's barely a year old. The deal centers on an "immune reset" drug that could reshape how we treat autoimmune diseases, and Gilead isn't even paying the full tab.
Eli Lilly is paying up to $7 billion for a tiny biotech that wants to reprogram your immune cells without ever taking them out of your body. It's the boldest bet yet in the race to make CAR-T therapy as simple as an IV drip.
A Paragon Therapeutics spinout just raised $290 million to chase a migraine target that isn't CGRP, going public through a reverse merger before testing its drugs in a single human. The investor roster is stacked, but the science is still unproven.
The FDA's new "plausible mechanism" framework could let gene therapies for ultra-rare diseases reach patients without massive clinical trials. It's the biggest regulatory shift in years, and it might finally fix the impossible economics that have kept cures on the shelf.
Join thousands of biotech professionals who start their day with our free, daily briefing.